On February 1, 2019, a U.S. district court issued a final judgment in favor of Roche/Genentech and against Shire, through its wholly-owned subsidiaries Baxalta Inc. and Baxalta GmbH. The judgment states that Hemlibra® (emicizumab-kxwh) does not infringe Shire’s patent (U.S. Patent, 7,033,590) based on the court’s definition of key terms related to the patent. This follows the court’s ruling in August 2018 denying the request from Shire for a preliminary injunction that intended to prevent certain patients in the U.S. from receiving Hemlibra. Since the case has been resolved in favor of Genentech, there is no longer a trial scheduled for September 2019.
